H.R. 3327 · 116th Congress
Drug Price Transparency for Medicare Patients Act of 2019
- Stage
- In committee
- Sponsor
- Francis Rooney
- Introduced
- 2019-06-18
- Latest action
- 2019-06-19 · Referred to the Subcommittee on Health.
Summary
Drug Price Transparency for Medicare Patients Act of 2019
This bill provides statutory authority for the Centers for Medicare & Medicaid Services rule titled "Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency," published on May 10, 2019. The rule requires direct-to-consumer television advertisements for covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule takes effect July 9, 2019.